Portal de investigación
Early carbohydrate antigen 125 as a mortality predictor in hospitalized patients with coronavirus disease 2019.
Fecha de publicación:
Fecha Ahead of Print:
Autores de INCLIVA
Participantes ajenos a INCLIVA
- Moreno-Perez, O
- Sandin-Rollan, M
- Arrarte, V
- Boix, V
- Reus, S
- Pinargote-Celorio, H
- Ribes, I
- Alfayate, R
- Llorca-Santos, MB
- Martinez-Garcia, MA
- Chico-Sanchez, P
- Merino, E
Grupos y Plataformas de I+D+i
Abstract
BACKGROUND: Carbohydrate antigen 125 (CA125) is an indicator of inflammation, immune response, and impaired cardiac function. The aim was to investigate whether CA125 behaves as a biomarker of severity and poor clinical outcomes in hospitalized patients with coronavirus disease 2019 (COVID-19). METHODS: Serum CA125 [Elecsys CA125 II assay-(Roche Diagnostics GmbH)] was measured in stored biobank samples from COVID-19 hospitalized patients between 01 March 2020 and 17 October 2021. Multiple logistic regression models were built to explore the association between CA125 and clinical outcomes [in-hospital all-cause mortality, need for invasive mechanical ventilation (IMV), or non-invasive respiratory support (non-IRS)], estimating odds ratios (ORs; 95% CI). The gradient of risk of CA125 was evaluated by fractional polynomials. RESULTS: A total of 691 patients were included, median age of 63 years (50-76), men (57.2%), with high comorbidity. At admission, 85.8% had pneumonia. Median CA125 was 10.33 U/ml (7.48-15.50). The in-hospital mortality rate was 7.2%. After adjusting for confounding factors, CA125 = 15.5 U/ml (75th percentile) showed an increased risk of death [OR 2.85(1.21-6.71)], as age = 65 years, diabetes, and immunosuppression. Furthermore, CA125 as a continuous variable was positive and significantly associated with the risk of death after multivariate adjustment. The mean hospital stay of the patients with CA125 = 15.5 U/ml was longer than the rest of the study population. CONCLUSION: CA125 in the first 72 h of hospital admission seems a useful biomarker of mortality in hospitalized patients with moderate-severe COVID-19. If our findings are confirmed, the wide availability of this biomarker would make easy its widespread implementation in clinical practice.
Copyright © 2022 Moreno-Perez, Nuñez, Sandin-Rollan, Arrarte, Boix, Reus, Pinargote-Celorio, Ribes, Alfayate, Llorca-Santos, Martinez-Garcia, Chico-Sánchez and Merino.
Datos de la publicación
- ISSN/ISSNe:
- 2297-055X, 2297-055X
- Tipo:
- Article
- Páginas:
- 941512-941512
- PubMed:
- 36337886
Frontiers In Cardiovascular Medicine FRONTIERS MEDIA SA
Documentos
Filiaciones
Keywords
- CA125; COVID-19; hospitalized; mortality; risk factors
Financiación
Proyectos y Estudios Clínicos
INCORPORACIÓN DE NUEVAS ÁREAS TEMÁTICAS Y NUEVOS GRUPOS AL CONSORCIO CIBER
Investigador Principal: JUAN SANCHIS FORES
CB16/11/00420 . INSTITUTO SALUD CARLOS III
Cita
Moreno O,Nunez J,Sandin M,Arrarte V,Boix V,Reus S,Pinargote H,Ribes I,Alfayate R,Llorca MB,Martinez MA,Chico P,Merino E. Early carbohydrate antigen 125 as a mortality predictor in hospitalized patients with coronavirus disease 2019. Front. Cardiovasc. Med. 2022. 9. p. 941512-941512. IF:3,600. (2).
Early carbohydrate antigen 125 as a mortality predictor in hospitalized patients with coronavirus disease 2019. Moreno O, Nunez J, Sandin M, Arrarte V, Boix V, Reus S, Pinargote H et al. Frontiers In Cardiovascular Medicine. 2022 octubre 20. 9941512-941512. DOI:10.3389/fcvm.2022.941512. PMID:36337886.
